No connection

Search Results

ABBV vs ICUI

ABBV
AbbVie Inc.
NEUTRAL
Price
$219.26
Market Cap
$387.52B
Sector
Healthcare
AI Confidence
68%
ICUI
ICU Medical, Inc.
BEARISH
Price
$125.68
Market Cap
$3.14B
Sector
Healthcare
AI Confidence
80%

Valuation

P/E Ratio
ABBV
163.63
ICUI
4189.33
Forward P/E
ABBV
15.42
ICUI
13.66
P/B Ratio
ABBV
-146.66
ICUI
1.46
P/S Ratio
ABBV
6.5
ICUI
1.41
EV/EBITDA
ABBV
15.27
ICUI
13.35

Profitability

Gross Margin
ABBV
71.46%
ICUI
36.84%
Operating Margin
ABBV
35.5%
ICUI
4.83%
Profit Margin
ABBV
4.0%
ICUI
0.03%
ROE
ABBV
137.96%
ICUI
0.04%
ROA
ABBV
9.59%
ICUI
1.66%

Growth

Revenue Growth
ABBV
9.1%
ICUI
-14.1%
Earnings Growth
ABBV
-88.7%
ICUI
--

Financial Health

Debt/Equity
ABBV
--
ICUI
0.63
Current Ratio
ABBV
0.72
ICUI
2.39
Quick Ratio
ABBV
0.47
ICUI
0.99

Dividends

Dividend Yield
ABBV
3.05%
ICUI
--
Payout Ratio
ABBV
490.15%
ICUI
0.0%

AI Verdict

ABBV NEUTRAL

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

Strengths
High operating margin (35.50%) indicating strong pricing power and cost control
Consistent revenue growth (9.10% YoY) outpacing sector average
Strong track record of earnings surprises (22 out of 25 quarters beat estimates)
Risks
Extremely high P/E ratio (163.63) vs forward P/E (15.42), suggesting potential overvaluation on trailing basis
Earnings growth collapsing (YoY: -88.70%, Q/Q: -88.10%) indicating severe profitability deterioration
Unsustainable dividend payout ratio (490.15%) threatening dividend security
ICUI BEARISH

ICUI presents a stark contradiction between a strong balance sheet and a collapsing income statement. While the Piotroski F-Score of 8/9 indicates exceptional structural financial health, the company is suffering from a severe earnings crisis, evidenced by a P/E ratio of 4189.33 and a -131.5% Q/Q EPS growth. The massive disconnect between the current price ($125.68) and the Graham Number ($7.62) suggests the stock is trading at a significant premium based on future recovery hopes rather than current fundamentals. With revenue declining by 14.1% and insiders selling, the strong health score is currently insufficient to offset the operational deterioration.

Strengths
Strong Piotroski F-Score (8/9) indicating high structural health
Healthy Current Ratio (2.39) showing strong short-term liquidity
Manageable Debt/Equity ratio (0.63)
Risks
Severe earnings collapse with recent Q/Q EPS growth of -131.5%
Negative revenue growth (-14.10% YoY) indicating market share loss or demand drop
Extreme valuation disconnect (Current P/E 4189.33 vs Forward P/E 13.66)

Compare Another Pair

ABBV vs ICUI: Head-to-Head Comparison

This page compares AbbVie Inc. (ABBV) and ICU Medical, Inc. (ICUI) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile